298 related articles for article (PubMed ID: 10470184)
21. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies.
Nakase K; Tsuji K; Tamaki S; Tanigawa M; Ikeda T; Miyanishi E; Shiku H
Cancer Detect Prev; 2005; 29(3):256-9. PubMed ID: 15899555
[TBL] [Abstract][Full Text] [Related]
22. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
Elg SA; Hill RB; Heldman L; Ramakrishnan S
Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
[TBL] [Abstract][Full Text] [Related]
23. [Soluble interleukin-2 receptor level in the sera and ascitic fluids in patients with ovarian cancer].
Pu FR; Cheng SW; Zhu D
Zhonghua Fu Chan Ke Za Zhi; 1994 Aug; 29(8):478-80, 511. PubMed ID: 7835120
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of soluble interleukin-2 receptor in patients with ANCA-associated vasculitis.
Arranz O; Ara J; Rodríguez R; Saurina A; Mirapeix E; Darnell A
J Nephrol; 2000; 13(1):59-64. PubMed ID: 10720216
[TBL] [Abstract][Full Text] [Related]
25. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
Ohno H; Ishikawa T; Kitajima H; Nomura S; Suzuki T; Konishi H; Ohno Y; Onishi R; Konaka Y; Arima N; Doi S; Nasu K; Takahashi T; Tsudo M; Fukuhara S; Uchiyama T
Rinsho Ketsueki; 2002 Mar; 43(3):170-5. PubMed ID: 11979748
[TBL] [Abstract][Full Text] [Related]
26. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
27. [The performance of the automated immune chemiluminescent system "IMMULITE 2000XPi for the measurement of serum soluble IL-2 receptor in clinical samples].
Watanabe N; Nagatomo R; Okubo S; Yokota H; Masuda A; Ikeda H; Yatomi Y
Rinsho Byori; 2012 May; 60(5):422-8. PubMed ID: 22774570
[TBL] [Abstract][Full Text] [Related]
28. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications.
Wasik MA; Vonderheid EC; Bigler RD; Marti R; Lessin SR; Polansky M; Kadin ME
Arch Dermatol; 1996 Jan; 132(1):42-7. PubMed ID: 8546482
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of serum biological markers in patients with hepatocellular carcinoma.
Parasole R; Izzo F; Perrone F; Pignata S; Galati MG; Leonardi E; Castiglione F; Orlando R; Castello G; Esposito G; Gallo C; Daniele B
Clin Cancer Res; 2001 Nov; 7(11):3504-9. PubMed ID: 11705869
[TBL] [Abstract][Full Text] [Related]
30. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
31. [Diagnostic and prognostic significance of serum soluble interleukin 2 receptor in children with malignancies].
Bień E; Balcerska A; Ciesielski D
Wiad Lek; 2006; 59(1-2):10-5. PubMed ID: 16646285
[TBL] [Abstract][Full Text] [Related]
32. [Serum level of the tumor marker CA 125 in ovarian pathology].
Bagni B; Pansini FS; Feggi LM; Prandini N; Mollica G
Radiol Med; 1987 Nov; 74(5):448-50. PubMed ID: 3479814
[TBL] [Abstract][Full Text] [Related]
33. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
[TBL] [Abstract][Full Text] [Related]
34. Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia.
Chrobák L; Podzimek K; Plísková L; Kerekes Z; Zák P; Voglová J; Spacek J; Palicka V
Neoplasma; 1996; 43(5):321-5. PubMed ID: 8996552
[TBL] [Abstract][Full Text] [Related]
35. The management of persistent clear pelvic cysts diagnosed by ultrasonography.
Hurwitz A; Yagel S; Zion I; Zakut D; Palti Z; Adoni A
Obstet Gynecol; 1988 Sep; 72(3 Pt 1):320-2. PubMed ID: 3043288
[TBL] [Abstract][Full Text] [Related]
36. Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma.
Wakao D; Murohashi I; Tominaga K; Yoshida K; Kishimoto K; Yagasaki F; Itoh Y; Itoh K; Sakata T; Kawai N; Kayano H; Suzuki T; Matsuda A; Hirashima K; Bessho M
Ann Hematol; 2002 Mar; 81(3):140-6. PubMed ID: 11904739
[TBL] [Abstract][Full Text] [Related]
37. [CEA, CA-19-9 and il-8, sTNFRII and sil-2R in persons at high risk of colorectal cancer].
Grotowski M; Wojtuń S
Pol Merkur Lekarski; 2003 Apr; 14(82):327-30. PubMed ID: 12868194
[TBL] [Abstract][Full Text] [Related]
38. [Soluble interleukin-2 receptor in patients with urinary bladder cancer].
Wen R; Xie S
Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):224-6. PubMed ID: 9387261
[TBL] [Abstract][Full Text] [Related]
39. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
40. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia.
Moon Y; Kim Y; Kim M; Lim J; Kang CS; Kim WI; Shim SI; Chung NG; Park YH; Min WS; Han K
Ann Clin Lab Sci; 2004; 34(4):410-5. PubMed ID: 15648782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
